Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 12%
Buy 35%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems Inc has demonstrated a robust commitment to increasing its advertising spend, which rose by 34% year-over-year to $100 million in 2023, leading to improved awareness and procedural growth in obstructive sleep apnea treatments. The company has also reiterated its revenue guidance for 2025, supported by a notable increase in earnings per share (EPS) following a strong third-quarter performance, which saw EPS projections raised by $0.50. Furthermore, expectations for increased average selling prices (ASPs) in 2026, paired with improved reimbursement prospects, suggest a favorable outlook for revenue growth and market penetration moving forward.

Bears say

Inspire Medical Systems has faced a decline in advertising expenses, with 2024 ad spend projected at $95 million, reflecting a year-over-year decrease of 5%. Management has revised its revenue and EPS outlook downward due to challenges associated with the launch of its new product, Inspire 5, resulting in expectations for slower adoption and growth. Additionally, a notable reduction in operating expenses, particularly in research and development, highlights a cautious approach that may hinder long-term revenue growth, further contributing to a negative sentiment on the company's stock.

INSP has been analyzed by 17 analysts, with a consensus rating of Buy. 12% of analysts recommend a Strong Buy, 35% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 17 analysts, INSP has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $111.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $111.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.